Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Abbott :'s Tendyne™ Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation

share with twitter share with LinkedIn share with facebook
share via e-mail
01/30/2020 | 10:01am EDT

ABBOTT PARK, Ill., Jan. 30, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its Tendyne Transcatheter Mitral Valve Implantation (TMVI) system received CE Mark and is now approved for use in Europe. This life-changing therapy treats significant mitral regurgitation (MR) in patients requiring a heart valve replacement and provides a safe and effective solution for MR patients who are not candidates for open-heart surgery or transcatheter mitral valve repair.

As the most common heart disease affecting the heart valves, MR is a debilitating, progressive and life-threatening condition in which the heart's mitral valve does not close completely, allowing blood to flow backward into the left atrium of the heart. Due to the complex nature of mitral valve disease and different patient anatomies, multiple treatment options for MR may be necessary. For patients at high-risk for open-heart surgery or in clinical situations when the mitral valve is too damaged for a successful repair with Abbott's MitraClip device, the Tendyne system offers a much-needed, alternative minimally invasive treatment option when the leaky valve needs to be replaced.

The Abbott Tendyne valve is a first-of-its-kind therapy to replace the mitral valve in patients in need of symptom relief and quality-of-life improvement without open surgery and when transcatheter mitral repair is not possible. Global trial results to date have demonstrated excellent procedural safety and have shown 98.9% of Tendyne patients experienced MR elimination at discharge which was sustained through one-year in this very sick patient group.  

"European approval for Abbott's Tendyne mitral valve replacement therapy provides the clinical community with a new choice in how we approach correcting a leaking mitral valve," said Hendrik Treede, M.D., professor of cardiac surgery, University Hospital Bonn, Germany. "For the first time outside of clinical trial settings, heart teams now have a minimally invasive valve replacement therapy that is backed by an excellent safety profile and designed to help physicians reposition the device as needed for improved patient outcomes." A post-approval study of the therapy will also be co-led by Nicolas Dumonteil, M.D., interventional cardiologist, Clinique Pasteur, France.

The Tendyne TMVI system can adapt to a range of patient anatomies thanks to its innovative and unique design. The self-expanding valve is delivered through a small incision in the chest and up through the heart where it is implanted in a beating heart, replacing the person's native mitral valve. The Tendyne valve is available in multiple sizes to treat a broad range of valve anatomies. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people suffering from MR and needing a valve replacement.

"The launch of the Tendyne device builds upon our history of developing groundbreaking therapies that offer new treatment options for people with serious structural heart conditions who have limited treatment options," said Michael Dale, senior vice president of Abbott's structural heart business. "The availability of Tendyne as a treatment option in Europe provides physicians with an additional tool that has been shown to completely correct MR in very ill patients, and it adds to Abbott's portfolio of life-changing and life-saving treatments."

Abbott is the global leader in developing transcatheter mitral valve technologies as alternatives to open-heart surgery. Building upon its success with the MitraClip device and many years of mitral valve experience and clinical evidence, Abbott is leading the way in novel, transcatheter devices by investing in the development and clinical study of minimally invasive technologies.  

For U.S. Important Safety Information about MitraClip, visit: https://www.structuralheartsolutions.com/us/mitraclip-isi.

The Tendyne Transcatheter Mitral Valve Implantation system is an investigational device in the U.S.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

Cision
View original content:http://www.prnewswire.com/news-releases/abbotts-tendyne-device-receives-worlds-first-ce-mark-for-transcatheter-mitral-valve-implantation-300995780.html

SOURCE Abbott


© PRNewswire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBOTT LABORATORIES
03/27ABBOTT : Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as..
PR
03/27Transmission of Annual Report for the Year Ended December 31, 2019 of Abbott ..
AQ
03/19ABBOTT : Hosts Conference Call for First-Quarter Earnings
PR
03/18ABBOTT LABORATORIES : Shipping 150,000 Coronavirus Tests
DJ
03/18ABBOTT : Receives FDA Emergency Use Authorization and Launches Test to Detect No..
PR
03/18Annual general meeting of Abbott Laboratories Limited to be held on April 20,..
AQ
03/06ABBOTT LABORATORIES : Aims to optimize tavi implants with european approval of f..
AQ
03/05ABBOTT : Aims to Optimize TAVI Implants with European Approval of FlexNav™..
PR
03/03The Race to Develop Tests to Spot Coronavirus-Linked Illness -- Update
DJ
03/03Hospitals, Companies Race to Develop Tests to Spot Coronavirus-Linked Illness
DJ
More news